### Original Article Apoptotic effects of Photofrin-Diomed 630-PDT on SHEEC human esophageal squamous cancer cells

Shegan Gao, Mengxi Zhang, Xiaojuan Zhu, Zhifeng Qu, Tanyou Shan, Xuanhu Xie, Ying Wang, Xiaoshan Feng

Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Luoyang, Henan, China

Received March 26, 2015; Accepted August 27, 2015; Epub September 15, 2015; Published September 30, 2015

**Abstract:** Photodynamic therapy (PDT) using photofrin-II is a clinically effective treatment for both non-neoplastic and neoplastic diseases. Herein, we performed an in vitro experiment to study the anti-tumor effect and mechanisms of photofrin-II mediated PDT for esophageal squamous cell carcinoma (ESCC) cell line, SHEEC. In this study, human ESCC cell line SHEEC and parental normal cell line SHEE were used. The anti-tumor effect of PDT was determined by evaluating cell viability using CCK-8 assay, apoptosis and generation of reactive oxygen species (ROS). PDT induced significant apoptosis in SHEEC and SHEE cells in a time- and photofrin-II dose-dependent manner. Furthermore, PDT treatment induced significant death of SHEEC, instead of SHEE cells. The apoptotic outcome was accompanied by concurrent generation of ROS. In summary, PDT shed light on therapy of ESCC, functioning as a useful tool for ESCC clinical treatment, providing a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

Keywords: SHEE, SHEEC, PDT, photofrin-II, apoptosis, ROS

#### Introduction

Operation, chemotherapy and radio therapy remains the most common methods of treating cancer, however, due to significant side effects of these treatments, Photodynamic therapy (PDT) was used as an alternative treatment for cancer patients. PDT is a light-based oncological and non-malignant diseases treatment modality, in which visible light is used to activate a photosensitizer, a light-absorbing molecule. Namely, the tumor-targeting photosensitizing molecule is administered followed by a light of a corresponding wavelength irradiation so as to induce the generation of reactive oxygen species (ROS) which was proven to be responsible for the DNA damage and cell death [1]. Dougherty etc has reported the significant clinical efficacy of PDT, which was later approved as the first drug-device combination by US Food and Drug Administration [2, 3]. To date, various tumors including esophagus cancer [4], gastric cancer [5], skin caner [6], head and neck cancer [7], etc have been treated by PDT.

It has been established that PDT could induce apoptotic, necrotic and autophagy cell death. Wu etc showed that ALA-mediated PDT initiated apoptotic cell death via the up-regulation and activation of p38 mitogen activated protein kinase (MAPK), the stress-activated c-jun Nterminal kinases (JNK) and ERK [8]; Mohamed etc demonstrated the results based on the cytoplasmic organelles and the intranuclear localization extensively enhanced the efficacy of PDT with appropriate photosensitizer and light dose and support the idea that PDT can contribute to elimination of malignant cells by inducing apoptosis, which is of physiological significance [9]; H Wang etc reported that DTPP showed an efficient growth inhibition of MCF-7 during PDT treatment [10].

Porfimer sodium (Photofrin II) is a photosensitizer which distributes selectively to tumor tissues, and causes tumor cell death by combination with light irradiation. Porfimer sodium is activated by laser irradiation at 630 nm, which can reacts with tissue oxygen to produce highly reactive excited siglet oxygen  $(10_2)$  [11]. It has been reported that photodynamic therapy is a safe and effective treatment for the palliation of obstructing and bleeding esophagus cancer [12], early unresectable lesions, palliation of locally advanced disease, and salvage therapy

### PDT promotes apoptosis of esophageal cancer

for stent blockage or local tumor recurrence [13, 14], Barrett's esophagus [15] and even esophageal candidiasis [16]. Moreover, photofrin-mediated PDT has been suggested to allow for preservation of function and structure of the larynx without systemic toxicity [17], to induce apoptosis and inhibit survival of human pancreatic cancer cells [18], to treat T1 and T2 oral squamous cell carcinoma [19]. Yang etc has reported the photofrin-associated inhibition of EGFR in esophageal squamous cell carcinoma cell line CE48T [20]. However, the molecular mechanisms in esophageal cancer during PDT remain unclear. In this study, we used human ESCC cell line SHEEC and parental normal cell line SHEE to study the anti-tumor effect of PDT by evaluating cell viability using CCK-8 assay, apoptosis and generation of reactive oxygen species (ROS). It was found that PDT induced significant apoptosis in SHEEC and SHEE cells in a time- and photofrin-II dose-dependent manner. Furthermore, PDT treatment induced significant death of SHEEC, instead of SHEE cells. The apoptotic outcome was accompanied by concurrent generation of ROS. Overall, this study provided a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

#### Materials and methods

#### Ethics statement

For tissue samples, written informed consent was obtained from patients. The procedures used in this study were approved by the Institutional Review Board of the Henan University of Science and Technology and was conformed to the Helsinki Declaration, and to local legislation.

#### Cell culture

SHEE human immortalized esophageal squamous cancer cells and the induced cancerous subline SHEEC were cultured in M199 culture medium (GIBCO, BRL Co. Ltd., USA), supplemented with 10% fetal ovine serum (FBS; Thermo Scientific Waltham, MA), gentamicin (50 mg/mL), penicillin (60 mg/mL) and streptomycin (100 mg/mL) at 37°C in a humidified incubator with 5% CO<sub>2</sub>.

#### Photosensitizer and laser light delivery system

Photofrin-II was purchased from Sinclair Pharmaceuticals Co., Ltd (Toronto, Canada). The laser used in this study was a DIOMED-630 (DIOMED Co., Hertfordshire, England) laser system using a semiconductor laser irradiator. The details of the settings in the laser system as well as the optimal doses of photofrin and laser irradiation in vitro and in vivo were as described previously [21, 22].

#### Photofrin-II-mediated PDT in cell culture

SHEE and SHEEC cells were placed into 96-well plates at a concentration of  $1 \times 10^4$  cells/well, incubated with photofrin-II (10 µg/ml) for 150 min, then were washed twice with PBS followed by incubation with M199 culture medium and finally cells were subjected to laser irradiation (wavelength, 630 nm; laser power, 25 mW/cm<sup>2</sup>; time, 25 s) [21] and harvested for apoptotic rates evaluation. Images of cellular fluorescence were captured using MetaMorph software (Molecular Devices, MDS Analytical Technologies) and the average pixel intensities were determined using morphometric analysis.

#### Quenching studies

SHEE and SHEEC cells were placed into 96-well plates at a concentration of  $1 \times 10^4$  cells/well, incubated with photofrin-II (10 µg/ml) for 150 min, then were washed twice with PBS followed by incubation with M199 culture medium supplemented with different levels of NaN<sub>3</sub>, and subjected to laser irradiation (wavelength, 630 nm; laser power, 25 mW/cm<sup>2</sup>; time, 50 s) [21].

## Annexin V/propidium iodide double-staining flow cytometry

The FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen 556547) was used to assess cell apoptosis induced by PDT treatment. Cells were harvested at 150 min after treatment with photofrin with or without subsequent irradiation. To analyze phosphatidyl serine exposure using 5 µl Annexin V-FITC staining and loss of cell membrane integrity using 5 µl Propidium Iodide (PI) staining. And were stained with annexin V-FITC and propidium iodide (PI). These cells were analyzed with flow cytometer (Beckman Coulter-EPICS XL, USA). Unstained cells were used as negative controls. Data collected were analyzed using the Beckman Coulter FACSDiva software (Beckman Coulter). Cells were discriminated into four groups: viable cells (annexin V-/PI-), necrotic dead cells (annexin V-/PI+), early apoptotic cells (annexin



V+/PI-) and late apoptotic cells (annexin V+/ PI+). Data was analyzed with FlowJo version7.6.5 (TreeStar, Ashland, USA).

#### MTT assay

The viability of cells incubated with photofrin of different concentration and for different time were examined by MTT (3-2,5-diphenyl tetrazolium bromide) assay (Sigma, USA) as described previously [23, 24]. After the culture medium was pipetted out, 50 mL MTT (2 mg/mL) was added to each well and cells were then incubated for 4 hours at 37°C. Solubilize the cells with DMSO (100 mL/well) for another 10 min, thoroughly mixed them by vibration for 5 min, and absorbance was measured at 540 nm.

#### Cell viability assays

After 24 hrs of PDT treatment, the number of viable cells was quantified using a Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan). A total of 10  $\mu$ l of CCK-8 solution was added into each well, and cells were then incubated for 3.5 hr at 37 °C in 5% CO<sub>2</sub>. Absorbance was measured at 450 nm using a microplate reader, according to the manufacturer's instructions. Relative inhibitory rate of cell growth was calculated according to the formula: Relative inhibitory rate = (A2-A1)/A2×100%, A1 is the mean absorbance of transfected cells, and A2



**Figure 1.** The fluorescence intensity of photofrin in cultured SHEE and SHEEC cells. A. The fluorescence intensity of photofrin in cultured SHEE and SHEEC cells at different wavelength; B. At different concentration of photofrin in culture medium, (Oneway ANOVA analysis, F = 2240.872, \*\*P < 0.001); C. For different incubation time of photofrin (One-way ANOVA analysis, F = 1948.160, \*\*P < 0.001). (The values indicate the mean ± SD, n = 3).

is the mean absorbance value of control groups. All experiments were performed with five wells per experiment in triplicate.

#### Measurement of intracellular ROS levels

The induction of intracellular ROS during PDT was examined using an OxiSelect Intracellular ROS assay kit (Cell Biolabs, Inc., San Diego, CA, USA), which uses the oxidation-sensitive fluorescent probe 29,79-dichlorodihydrofluorescein diacetate (DCFH-DA). This assay was performed by adding DCFH-DA to cells 4 h after PDT and quantifying intracellular ROS levels by detecting oxidized fluorescent 29,79-dichlorodihy-drofluorescein (DCF) using a fluorometric imaging plate reader (ARVOX5; PerkinElmer, Waltham, MA, USA) at 480/530 nm.

#### Soft agar colony-formation assays

2.5×10<sup>4</sup> cells of SHEEC cells were suspended in 0.67% agarose containing media with or without photofrin (30 mg/mL), with 1% agarose containing the medium per well on top of it. Then, the gel was laser irradiated 24 h after the gel formation, and cells were allowed to grow for another 2 weeks. Colonies were stained with 0.02% Giemsa Stain Solution (Santa Cruz Biotechnology, Inc Tokyo, Dallas, Texas, U.S.A), and the number and the size of colonies per high-power field were measured later.



Figure 2. Cytotoxic effect of photofrin-mediated PDT on SHEE and SHEEC cells. Cell viability was assessed using the MTT assay. A-C: Cell viability of SHEE cells (One-way ANOVA analysis, A: F = 7.858, P = 0.005; B: F = 9.868, P = 0.002; C: F = 13.417, \*\*P < 0.001); D-F: Cell viability of SHEEC cells (One-way ANOVA analysis, D: F = 8.141, P = 0.004; E: F = 8.273, P = 0.004; F: F = 11.043, P = 0.001). (The values indicate the mean  $\pm$  SD, n = 3).

#### Statistical analyses

Statistical analyses of Quenching studies, apoptosis assay, MTT assay, Cell Viability Assays intracellular ROS levels, and Soft agar colony-formation assays were performed by One-Way Anova with Bonferroni post-test (comparing all groups) or Dunnett post-test (comparing all groups) or Dunnett post-test (comparing all groups to a control group) using the SPSS statistics software (version 17; SPSS Inc., Chicago, IL, USA). Differences in values were considered as significant if the *P*-value was less than 0.05. All experiments were conducted at least 3 times and presented as Mean  $\pm$  S.D. and were analyzed by a 2-tailed paired t-test.

#### Results

# Measurement of photofrin in cultured SHEE and SHEEC cells

First, the absorption spectroscopy of culture medium was examined and 630nm was used in this study according to the results showed in **Figure 1A**. Then the uptake of photofrin by cultured SHEE and SHEEC cells was examined by the fluorescence spectrophotometer. As shown in **Figure 1**, when incubated for 120 min, photofrin was incorporated in SHEE and SHEEC cells in a dose-dependent manner; when incubated at specific concentration of photofrin, photofrin uptake peaked at 150 min.

## Cytotoxic effect of photofrin on SHEE and SHEEC cells

To examine the cytotoxic effect of photofrin in SHEE and SHEEC cells, we examined the cell viability using a MTT assay after photofrinmediated PDT. As shown in **Figure 2**, neither photofrin alone nor diode laser alone exhibited cytotoxicity in SHEE and SHEEC cells; however, photofrin incubation followed by laser irradiation induced an apparent time and dose-dependent cytotoxicity.

## Induction of apoptosis by photofrin-mediated PDT in SHEE and SHEEC cells

Annexin V/Propidium iodide double-staining flow cytometry was performed after cells were treated with photofrin-mediated PDT. As shown in **Figure 3**, photofrin-mediated PDT induced significant apoptosis of SHEE and SHEEC cells. Moreover, the late apoptosis rates of SHEEC cells both in experimental groups and in control groups were significantly lower than that of SHEE cells.

#### Increased levels of intracellular ROS by photofrin-mediated PDT

Previous study showed that the induction of ROS was one of the key mechanisms by which PDT could exert cell-killing effect [1, 25]. To examine whether SHEEC cells treated with photofrin-mediated PDT display increased levels of intracellular ROS, we used the oxiSelect intracellular ROS assay kit to evaluate the intracellular ROS level. As shown in Figure 4, the DCF assay revealed that intracellular ROS levels were significantly elevated by P-PDT in a photofrin dose (Figure 4A) and time (Figure **4B**)-dependent manner.  $NaN_3$  is the quencher of  $10_{2}$  [26], which belongs to ROS and is the excited state of O2. Pretreatment of NaN3 resulted in the suppression of cell-killing effect in a dose-dependent manner (Figure 4C, 4D).

Photofrin-mediated PDT inhibited anchorageindependent cell growth of SHEEC cells

Soft agar assay is an effective way to evaluate the anchorage-independent cell growth [27]. Hence, soft agar assay was used to examine whether photofrin-mediated PDT affects the anchorage-independent cell growth of SHEEC cells. As shown in **Figure 5**, neither photofrin alone nor irradiation alone affected the cell colony formation; however, photofrin-mediated PDT significantly suppressed the colony formation.

#### Discussion

In this study, we demonstrated that photofrin was incorporated in SHEE and SHEEC cells in a dose-dependent manner; when incubated at specific concentration of photofrin, photofrin uptake peaked at 150 min; photofrin incubation followed by laser irradiation induced an apparent time and dose-dependent cytotoxicity; the DCF assay revealed that intracellular ROS levels were significantly elevated by P-PDT in a photofrin dose and time-dependent manner; photofrin-mediated PDT significantly suppressed the colony formation. Namely, PDT shed light on therapy of ESCC, functioning as a useful tool for ESCC clinical treatment, provid-



**Figure 3.** Induction of apoptosis in SHEE and SHEEC cells treated with photofrin-mediated PDT(P-PDT). Proportion rates of cells treated with P-PDT( photofrin 10  $\mu$ g/ml) for different time, A. SHEEC cells, B. SHEE cells; Proportion rates of cells treated with P-PDT (photofrin 30  $\mu$ g/ml) for 150 min, C. SHEEC cells, D. SHEE cells, E. Flow cytometric analysis of apoptosis in SHEEC cells, F. Flow cytometric analysis of apoptosis in SHEEC cells, F. Flow cytometric analysis of apoptosis in SHEEC cells, F. Flow cytometric analysis of apoptosis in SHEEC cells, F. Flow cytometric analysis of apoptosis in SHEEC cells, F. Flow cytometric analysis of apoptosis in SHEEC cells, Cone-way ANOVA analysis for proportion rates of late apoptosis, A. F = 13.776, \*\*P < 0.001; B. F = 172.167, \*\*P < 0.001; C. F = 276.763, \*\*P < 0.001; D. F = 451.461, \*\*P < 0.001).

ing a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

Previous studies have showed that PDT was en effective way for suppressing the development

and metastasis ability of tumors, and multiple photosensitizers have been used to perform PDT [1, 28, 29]. For example, Shinya et al used human ESCC cells, TE-5, TE-8, TE-10 and TE-11, to examine the cytotoxic effect of talaporfin



**Figure 4.** Induction of ROS in SHEEC cells treated with photofrin-mediated PDT (P-PDT). A. The relative fluorescence intensity of SHEEC cells at different concentration of photofrin (One-way ANOVA analysis, F = 5.156, \*P = 0.0240); B. For different incubation time of photofrin (One-way ANOVA analysis, F = 9.643, \*\*\*P = 0.0009). (The values indicate the mean  $\pm$  SD, n = 3); C. Cell viability rate of SHEEC cells with the pretreatment different concentrations of NaN<sub>3</sub> at, 1: 0.0%, 2: 0.001%, 3: 0.01%, 4: 0.1% (One-way ANOVA analysis, F = 55.33, \*\*\*P < 0.0001). D. Cell viability rate of SHEEC cells with the pretreatment of NaN<sub>3</sub> when different dose of photofrin was used (One-way ANOVA analysis, F = 6.104, \*P = 0.0358).



**Figure 5.** Inhibition of anchorage-independent cell growth in SHEEC cells treated with photofrin-mediated PDT (P-PDT). A. The colony number of SHEEC cells (One-way ANOVA analysis, F = 6.382, \*\*P = 0.0013); B. The colony size of SHEEC cells (One-way ANOVA analysis, F = 7.643, \*\*P = 0.0040). (The values indicate the mean  $\pm$  SD, n = 3).

Sodium-Mediated PDT (t-PDT) and demonstrated that t-PDT induced potent cytotoxicity in ESCC cells independent of their differentiation grade or 5-FU resistance; moreover, t-PDT also induced robust apoptosis, perinuclear vacuolization, nuclear fragmentation and induction of annexin V-positive cells and this apoptotic response was accompanied by concurrent activation of ROS, and induction of DNA double-strand breakage [30]. CRISTINA et al have found that HEp-2 cells did not express  $\beta$ -integrin or FAK 12 h following PDT, that is, the PDT

reduces the adhesive ability of HEp-2 cells, inhibiting their metastatic potential; PDT using 5-aminolevulinic acid (ALA) is one of the promising treatments for malignant tumor because of its selectivity, low toxicity, rapid effect, and rapid clearance from the body [31]; Hypericin, a promising photosensitizer in the context of clinical photodynamic therapy due to its excellent photosensitizing properties and tumoritropic characteristics. Hypericin-PDT induced cytotoxicity elicits tumor cell death by various mechanisms including apoptosis, necrosis and autophagy-related cell death [32].

Further study displayed that specific signaling pathways were involved with the PDT efficacy [8, 33, 34]. Based on system biology models of the molecular interactions involved in the PDT processes previously established, and regarding a cellular decision-making system as a noisy communication channel, loannis used rate distortion theory to design a time dependent Blahut-Arimoto algorithm where the input was a stimulus vector composed of the time dependent concentrations of three PDT related cell death signaling molecules and the output is a cell fate decision [35].

Moreover, some molecules have been found to be useful to enhance the efficacy of PDT. 5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) catalyzes the first committed step of heme biosynthesis in animals. The erythroid-specific ALAS isozyme (ALAS2) is negatively regulated by heme at the level of mitochondrial import and, in its mature form, certain mutations of the murine ALAS2 active site loop result in increased production of protoporphyrin IX (PPIX), the precursor for heme. Light treatments revealed that ALAS2 expression results in an increase in cell death in comparison to aminolevulinic acid (ALA) treatment producing a similar amount of PPIX. The delivery of stable and highly active ALAS2 variants has the potential to expand and improve upon current PDT regimes [24]. Another study showed that the treatment of combination of inhibitors of FECH and ABCG2 could improve PPIX accumulation and PDT efficacy.

However, limited reports on the efficacy of this photofrin for the treatment of esophageal cancer have been published to date. Our results demonstrated that PDT shed light on therapy of ESCC, functioned as a useful tool for ESCC clinical treatment, and provided a better understanding of Photofrin-Diomed 630-PDT in SHEEC cells.

#### Acknowledgements

Supported by Henan provincial health department Key project (No. 201001008, 2013), Henan provincial technological key project (No. 112300410314) National Natural Science Foundation of China, No. 81301763, Henan Provincial Key Scientific and Technological Projects (No. 142102310473).

#### Disclosure of conflict of interest

#### None.

Address correspondence to: Ying Wang and Xiaoshan Feng, Oncology Department of The First Affiliated Hospital of Henan University of Science and Technology, No. 24 Jinghua Road, Luoyang, Henan, China. Tel: + 86 379 64811269; E-mail: yingw\_215@163.com (YW); samfeng137@hotmail. com (XSF)

#### Referrences

- [1] Robertson C, Evans DH and Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 2009; 96: 1-8.
- [2] Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol 1984; 2: 83-116.
- [3] Mang TS and Dougherty TJ. Time and sequence dependent influence of in vitro photodynamic therapy (PDT) survival by hyperthermia. Photochem Photobiol 1985; 42: 533-540.
- [4] Lightdale CJ, Heier SK, Marcon NE, McCaughan JS Jr, Gerdes H, Overholt BF, Sivak MV Jr, Stiegmann GV and Nava HR. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42: 507-512.
- [5] Mimura S, Ito Y, Nagayo T, Ichii M, Kato H, Sakai H, Goto K, Noguchi Y, Tanimura H and Nagai Y. Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer. Lasers Surg Med 1996; 19: 168-172.
- [6] Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM and Morton CA. Guidelines on

the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-143.

- [7] Lou P, Jäger H, Jones L, Theodossy T, Bown S and Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004; 91: 441-446.
- [8] Wu R, Yow C, Wong C and Lam Y. Photodynamic therapy (PDT)-Initiation of apoptosis via activation of stress-activated p38 MAPK and JNK signal pathway in H460 cell lines. Photodiagnosis Photodyn Ther 2011; 8: 254-263.
- [9] Ali-Seyed M, Bhuvaneswari R, Soo KC and Olivo M. Photolon<sup>™</sup>-Photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Int J Oncol. 2011; 39: 821-831.
- [10] Wang H, Zhang HM, Yin HJ, Zheng LQ, Wei MQ, Sha H and Li YX. Combination of a Novel Photosensitizer DTPP with 650 nm Laser Results in Efficient Apoptosis and Cytoskeleton Collapse in Breast Cancer MCF-7 Cells. Cell Biochem Biophys 2014; 69: 549-54.
- [11] Tsukagoshi S. [Porfimer sodium (Photofrin-II)]. Gan to kagaku ryoho. Cancer Chemother 1995; 22: 1271-1278.
- [12] Luketich J, Christie N, Buenaventura P, Weigel T, Keenan R and Nguyen N. Endoscopic photodynamic therapy for obstructing esophageal cancer: 77 cases over a 2-year period. Surg Endosc 2000; 14: 653-657.
- [13] Moghissi K. Where does photodynamic therapy fit in the esophageal cancer treatment jigsaw puzzle? J Natl Compr Canc Netw 2012; 10 Suppl 2: S52-S55.
- [14] Moghissi K and Dixon K. Photodynamic therapy (PDT) in esophageal cancer: a surgical view of its indications based on 14 years experience. Tech Cancer Res Treat 2003; 2: 319-326.
- [15] Foroulis CN and Thorpe JA. Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. Eur J Cardio Thorac Surg 2006; 29: 30-34.
- [16] Qiu H, Mao Y, Gu Y, Zhu J, Wang Y, Zeng J, Huang N, Liu Q and Yang Y. The potential of photodynamic therapy to treat esophageal candidiasis coexisting with esophageal cancer. J Photochem Photobiol B 2014; 130: 305-309.
- [17] Silbergleit AK, Somers ML, Schweitzer VG, Gardner GM and Peterson E. Vocal Fold Vibration After Photofrin-Mediated Photodynamic Therapy for Treatment of Early-Stage Laryngeal Malignancies. J Voice 2013; 27: 762-764.
- [18] Wang LW, Huang Z, Lin H, Li ZS, Hetzel F and Liu B. Effect of Photofrin-mediated photocyto-

toxicity on a panel of human pancreatic cancer cells. Photodiagnosis Photodyn Ther 2013; 10: 244-251.

- [19] Ikeda H, Tobita T, Ohba S, Uehara M and Asahina I. Treatment outcome of Photofrinbased photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia. Photodiagnosis Photodyn Ther 2013; 10: 229-235.
- [20] Yang PW, Hung MC, Hsieh CY, Tung EC, Wang YH, Tsai JC and Lee JM. The effects of Photofrinmediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers Med Sci 2013; 28: 605-614.
- [21] Brancaleon L and Moseley H. Laser and nonlaser light sources for photodynamic therapy. Lasers Med Sci 2002; 17: 173-186.
- [22] Chen X, Zhao P, Chen F, Li L and Luo R. Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. Lasers Med Sci 2011; 26: 69-78.
- [23] Seidl K and Zinkernagel AS. The MTT assay is a rapid and reliable quantitative method to assess Staphylococcus aureus induced endothelial cell damage. J Microbiol Methods 2013; 92: 307-309.
- [24] Fratz EJ, Hunter GA and Ferreira GC. Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death. PLoS One 2014; 9: e93078.
- [25] Dewaele M, Martinet W, Rubio N, Verfaillie T, de Witte PA, Piette J and Agostinis P. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J Cell Mol Med 2011; 15: 1402-1414.
- [26] Chakraborty N and Tripathy BC. Involvement of singlet oxygen in 5-aminolevulinic acid-induced photodynamic damage of cucumber (Cucumis sativus L.) chloroplasts. Plant Physiol 1992; 98: 7-11.
- [27] de Larco JE and Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A 1978; 75: 4001-4005.
- [28] Ferrario A, Rucker N, Wong S, Luna M and Gomer CJ. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res 2007; 67: 4989-4995.
- [29] Dolmans DE, Fukumura D and Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-387.
- [30] Ohashi S, Kikuchi O, Tsurumaki M, Nakai Y, Kasai H, Horimatsu T, Miyamoto Si, Shimizu A, Chiba T and Muto M. Preclinical Validation of Talaporfin Sodium-Mediated Photodynamic Therapy for Esophageal Squamous Cell Carcinoma. PLoS One 2014; 9: e103126.

- [31] Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q. Photodynamic therapy. J Natl Cancer Instit 1998; 90: 889-905.
- [32] Kleemann B, Loos B, Scriba TJ, Lang D and Davids LM. St John's Wort (Hypericum perforatum L.) Photomedicine: Hypericin-Photodynamic Therapy Induces Metastatic Melanoma Cell Death. PLoS One 2014; 9: e103762.
- [33] Ahmad N, Kalka K and Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001; 20: 2314-2317.
- [34] Wu Y and Chen WR. Methodlogical Report Single Cell FRET Imaging for Determination of Pathway of Tumor Cell Apoptosis Induced by Photofrin-PDT. Cell Cycle 2006; 5: 729-734.
- [35] Gkigkitzis I. Theoretical aspects and modelling of cellular decision making, cell killing and information-processing in photodynamic therapy of cancer. BMC Med Genomics 2013; 6 Suppl 3: S3.